| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CKM |
| Uniprot No | P06732 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-381aa |
| 氨基酸序列 | MPFGNTHNKFKLNYKPEEEYPDLSKHNNHMAKVLTLELYKKLRDKETPSGFTVDDVIQTGVDNPGHPFIMTVGCVAGDEESYEVFKELFDPIISDRHGGYKPTDKHKTDLNHENLKGGDDLDPNYVLSSRVRTGRSIKGYTLPPHCSRGERRAVEKLSVEALNSLTGEFKGKYYPLKSMTEKEQQQLIDDHFLFDKPVSPLLLASGMARDWPDARGIWHNDNKSFLVWVNEEDHLRVISMEKGGNMKEVFRRFCVGLQKIEEIFKKAGHPFMWNQHLGYVLTCPSNLGTGLRGGVHVKLAHLSKHPKFEEILTRLRLQKRGTGGVDTAAVGSVFDVSNADRLGSSEVEQVQLVVDGVKLMVEMEKKLEKGQSIDDMIPAQK |
| 预测分子量 | 70.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CKM(肌酸激酶同工酶)重组蛋白研究的模拟参考文献(非真实文献，示例格式)：
---
1. **《重组人CKM蛋白在大肠杆菌中的高效表达及纯化》**
- 作者：Zhang L, Wang Y, et al.
- 摘要：研究通过基因工程技术将人源CKM基因克隆至大肠杆菌表达系统，优化表达条件后获得可溶性重组蛋白，并通过亲和层析纯化，为CKM的体外功能研究提供高纯度材料。
2. **《CKM重组蛋白在心肌损伤诊断中的临床应用评估》**
- 作者：Smith J, Tanaka K.
- 摘要：通过哺乳动物细胞表达系统制备重组CKM蛋白，开发新型免疫检测方法，验证其在血清中心肌损伤标志物的灵敏度和特异性，推动心血管疾病早期诊断技术发展。
3. **《CKM重组蛋白结构解析及其与底物结合机制》**
- 作者：Chen H, et al.
- 摘要：利用X射线晶体学解析重组CKM蛋白的三维结构，结合分子动力学模拟揭示其催化活性中心与肌酸/ATP的结合模式，为设计靶向抑制剂提供理论依据。
---
注：以上为模拟文献，实际研究中建议通过PubMed、Web of Science等平台检索真实文献。
**Background of CKM Recombinant Protein**
CKM (creatine kinase, M-type) is a key enzyme in cellular energy metabolism, primarily expressed in skeletal muscle, heart, and brain tissues. It catalyzes the reversible transfer of phosphate groups between creatine and adenosine triphosphate (ATP), playing a critical role in maintaining energy homeostasis, particularly in tissues with high and fluctuating energy demands. Dysregulation of CKM is associated with various pathologies, including muscular dystrophy, myocardial infarction, and neurodegenerative disorders.
Recombinant CKM protein is produced using genetic engineering techniques, where the *CKM* gene is cloned into expression vectors (e.g., bacterial, yeast, or mammalian systems) to enable large-scale, purified protein production. This approach ensures consistency, scalability, and reduced contamination risks compared to tissue-extracted forms. Recombinant CKM retains native enzymatic activity and structural integrity, making it valuable for research and therapeutic applications.
In research, recombinant CKM is used to study energy metabolism mechanisms, model diseases *in vitro*, screen potential drugs targeting metabolic disorders, and develop diagnostic assays (e.g., detecting muscle damage biomarkers). Therapeutically, it holds exploratory potential for treating conditions linked to energy deficits, such as heart failure or muscle atrophy. Challenges include optimizing expression systems for proper post-translational modifications and ensuring stability in delivery formats.
Overall, recombinant CKM serves as a vital tool in bridging biochemical insights with clinical innovations, offering opportunities to advance both basic science and translational medicine.
×
